Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Genentech

< Previous 1 2 3 4 Next >
Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
From Genentech
Via Business Wire
Tickers OTC
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
From Genentech
Via Business Wire
Tickers RHHBY
New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder
From Genentech
Via Business Wire
Tickers RHHBY
New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
From Genentech
Via Business Wire
Tickers RHHBY
Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
From Genentech
Via Business Wire
Tickers RHHBY
New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
From Genentech
Via Business Wire
Tickers RHHBY
Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
From Genentech
Via Business Wire
Tickers RHHBY
New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
From Genentech
Via Business Wire
Tickers RHHBY
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.